{"id":3226,"date":"2026-09-18T09:00:00","date_gmt":"2026-09-18T13:00:00","guid":{"rendered":"https:\/\/www.insilens.com\/?p=3226"},"modified":"2026-09-19T13:53:09","modified_gmt":"2026-09-19T17:53:09","slug":"fda-approves-aqneursa-for-ataxia-telangiectasia","status":"publish","type":"post","link":"https:\/\/www.insilens.com\/?p=3226","title":{"rendered":"FDA Approves Aqneursa for Ataxia-Telangiectasia"},"content":{"rendered":"

\"\"<\/p>\n

Company<\/strong><\/p>\n

IntraBio<\/p>\n

Event Type<\/strong><\/p>\n

FDA Approval (Indication Expansion)<\/p>\n

Modality<\/strong><\/p>\n

Small Molecule (L-Enantiomer of Acetylleucine)<\/p>\n

Asset<\/strong><\/p>\n

Aqneursa (Levacetylleucine)<\/p>\n

Disease Area<\/strong><\/p>\n

Ataxia-Telangiectasia (Neurologic Manifestations)<\/p>\n

Summary<\/h4>\n

FDA expanded Aqneursa, levacetylleucine, to treat ataxia in adults and children with ataxia-telangiectasia who weigh at least 15 kilograms. It is the first approved treatment for the neurologic manifestation of this rare ATM-deficiency disorder. The randomized, double-blind, placebo-controlled crossover study enrolled 73 participants and showed improvement on clinician-rated ataxia scales over 12 weeks. The result is clinically important and more rigorous than an uncontrolled rare-disease dataset, but it establishes short-term symptomatic benefit rather than disease modification, and the drug’s molecular target remains unknown.<\/p>\n

FDA announced the approval on September 18, 2026; it was recovered in the September 19 reconciliation after the morning package. In study IB1001-303, 73 participants aged four to 50 years entered two randomized 12-week treatment periods of levacetylleucine and placebo, and 70 completed both periods. FDA states that the functional Scale for the Assessment and Rating of Ataxia analysis favored treatment. The peer-reviewed report described a mean conventional SARA change of −1.92 with treatment versus −0.14 with placebo, with a treatment difference of −1.88 and P less than 0.001; the conventional and functional SARA analyses should not be conflated.<\/p>\n

The publication also reported favorable secondary outcomes on ICARS and clinician global impression. The company reported no drug-related serious adverse event in the pivotal study. FDA lists falls, skin laceration, and urinary-tract infection among common adverse reactions, warns of embryo-fetal toxicity, and advises against concomitant N-acetyl-DL-leucine. Aqneursa was previously approved for neurologic manifestations of Niemann–Pick disease type C; the A-T label is a separate indication supported by a distinct controlled trial.<\/p>\n

Deep Analysis<\/h4>\n

One interpretation is that levacetylleucine produces a reproducible short-term improvement in cerebellar motor function across a genetically defined A-T population. The randomized crossover design, concordant clinician-rated endpoints, high completion rate, and regulatory review support that reading. Against it, the treatment periods were brief, crossover trials can be sensitive to period and carryover effects, and the absolute scale change requires context from patient-reported function and durability. A second interpretation is that the drug addresses a convergent cellular-stress or energy-homeostasis phenotype shared across neurodegenerative lysosomal and DNA-repair disorders. Approval in both NPC and A-T is consistent with that possibility, but an unknown target and absence of direct human target-engagement data prevent a mechanism-level conclusion.<\/p>\n

Company and Product Background<\/h4>\n

Ataxia-telangiectasia is caused by biallelic ATM variants that impair DNA-damage signaling and produce progressive cerebellar degeneration, immunodeficiency, pulmonary vulnerability, and elevated cancer risk. Aqneursa is the L-enantiomer of acetylleucine and is administered orally according to body weight. Proposed effects on membrane potential, glucose and energy metabolism, lysosomal function, and neuronal homeostasis remain incompletely resolved; none establishes a validated molecular target or a claim of modifying the multisystem disease.<\/p>\n

Signal Extraction<\/h4>\n
    \n
  • Aqneursa fills a genuine therapeutic gap and rests on controlled evidence in an ultra-rare disease.<\/li>\n
  • Upgrades with:<\/strong> durable improvements in mobility, falls, speech, activities of daily living, school participation, and caregiver burden; sustained benefit during extension follow-up; a favorable pediatric safety profile; and biomarkers linking exposure to neuronal function.<\/li>\n
  • Downgrades if:<\/strong> scale gains do not translate into daily function, attenuate with time, depend on crossover assumptions, or are offset by treatment burden or pregnancy restrictions.<\/li>\n
  • Falsified if:<\/strong> long-term neurologic decline proceeds unchanged despite persistent short-term symptomatic improvement.<\/li>\n<\/ul>\n

    InSilens Take<\/h4>\n

    Aqneursa fills a genuine therapeutic gap and rests on controlled evidence in an ultra-rare disease. The approval should be framed as symptomatic treatment of ataxia, not correction of ATM deficiency or proof of slowed neurodegeneration. The next decisive evidence is whether short-term scale improvement persists and reduces falls, disability, and caregiver burden in routine use.<\/p>\n

    Signal Assessment<\/h4>\n

    Signal strength:<\/strong> 5\/5 — first FDA-approved therapy for ataxia in A-T, supported by a randomized controlled trial. Importance:<\/strong> Positive — approval establishes short-term neurologic benefit in a disease with no prior indicated therapy. Confidence:<\/strong> High on facts (FDA, the trial registry, and the peer-reviewed report align on design, population, and outcome direction); moderate on interpretation (durability, real-world functional benefit, and mechanism remain unresolved).<\/p>\n","protected":false},"excerpt":{"rendered":"

    FDA expanded Aqneursa, levacetylleucine, to treat ataxia in adults and children with ataxia-telangiectasia who weigh at least 15 kilograms. It is the first approved treatment for the neurologic manifestation of this rare ATM-deficiency disorder….<\/p>\n","protected":false},"author":1,"featured_media":3243,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[788,789,790],"class_list":["post-3226","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-ataxia-telangiectasia","tag-intrabio","tag-rare-disease"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3226"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3226\/revisions"}],"predecessor-version":[{"id":3250,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3226\/revisions\/3250"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3243"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}